SYRE — Spyre Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $2.61bn
- $2.23bn
- 35
- 15
- 86
- 42
Annual income statement for Spyre Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 18.7 | 2.33 | 0.886 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 81.5 | 84.4 | 87.1 | 243 | 209 |
| Operating Profit | -81.5 | -65.6 | -84.8 | -242 | -209 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -80.9 | -65.7 | -84 | -339 | -208 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -80.9 | -65.8 | -83.8 | -339 | -208 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -80.9 | -65.8 | -83.8 | -339 | -208 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -80.9 | -65.8 | -83.8 | -339 | -208 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -37.9 | -25 | -24.9 | -30.8 | -4.42 |